Viswa Colluru

Founder & CEO @envedabio I Son, husband, and teammate I India ‣ US for PhD @UWMadison I Love solving hard problems with amazing people

[Viswa Colluru @viswacolluru]

Another one to round out a big year at Enveda! 130 million more chances to deliver new hope to patients, the work experience of a lifetime for our employees, incredible returns to our investors, breakthrough technology to the world, and knowledge (Veda) to humanity 🚀

[Enveda @lifeschemistry]

We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials.

In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team.

This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible.

Here’s to the next chapter of growth, discovery, and development! 💊💡

Learn more here: https://t.co/4Dxa2Vc8U1

Read our feature in @Bloomberg here: https://t.co/1rFLlt65Ut

[Enveda @lifeschemistry]

The potential of #AI in #DrugDiscovery has been discussed for a while, with little to show for it in the clinic.

Enveda is changing that. Positive clinical readout, multiple mega-blockbuster clinical pipeline, and a platform that is expanding our understanding of biology through chemistry.

Our Founder & CEO, @viswacolluru, will present at the @UBS Private Biotech Innovation Summit on May 18, one of the most selective investor forums for private biopharma companies.

Clinical proof that our AI-native platform can produce differentiated medicines at scale, not just interesting molecules. See you there!

[Mario Gabriele @mariogabriele]

.@viswacolluru thinks most ideas that change the trajectory of human life are actually old. The locomotive was first a steam engine. Electric cars, neural networks, and rockets all existed long before the world caught up to them.

The question is not what to invent but which abandoned idea the world is finally ready to revisit, where the ancillary technologies have matured enough to clear the original constraints.

For Viswa, that idea is using plant compounds as the starting point for drug discovery. The pharma industry set it aside, and he is revisiting it.

[Enveda @lifeschemistry]

This Earth Day, we're reflecting on a simple but powerful idea: 𝗻𝗮𝘁𝘂𝗿𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗿𝘂𝗻𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗼𝗻𝗴𝗲𝘀𝘁 𝗥&𝗗 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝗶𝗻 𝗵𝗶𝘀𝘁𝗼𝗿𝘆.

Life on Earth has built an extraordinary library of chemistry. Molecules shaped by survival, adaptation, and symbiosis. These compounds weren't designed in a lab. They were selected by nature to solve real biological challenges.

At Enveda, we see this as an invitation. 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘄𝗲 𝗰𝗼𝘂𝗹𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝘁𝗵𝗶𝘀 𝘃𝗮𝘀𝘁, 𝗹𝗮𝗿𝗴𝗲𝗹𝘆 𝘂𝗻𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝗱 𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝘀𝗽𝗮𝗰𝗲? 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗲𝗻𝗰𝗼𝗱𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱 𝗮𝗿𝗼𝘂𝗻𝗱 𝘂𝘀?

Protecting biodiversity isn't just about preserving ecosystems. It's about safeguarding a living, evolving source of insight into human health.

This Earth Day, we're reminded that the future of medicine may depend on how well we listen to nature.

#EarthDay #Biodiversity #DrugDiscovery #NatureInspired

[Viswa Colluru @viswacolluru]

Pharma spent 30 years going biology-first. Enveda is built on the opposite bet.

On @generalist with @mariodgabriele: why the chemistry 4 billion years of evolution has already selected for is still the best starting material we have ...and why that question is personal for me.

[Mario Gabriele @mariogabriele]

For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@lifeschemistry), has raised over $500 million to build a “search engine for nature’s chemistry.”

In our conversation, we explore:
• Why the pharmaceutical industry abandoned nature (and why that was a massive mistake)
• How Enveda built a system to decode unknown molecules in nature
• The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work
• Why old ideas, from immunotherapy to natural products, often hold the most latent potential
• How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million
• Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis
• Why first-in-class medicines capture the vast majority of returns in pharma
• What competitive table tennis taught him about building companies

Thank you to the partners who make this possible
@brexHQ: The intelligent finance platform: https://t.co/WsjMETvEON
@ahrefs Brand Radar: Find your brand in AI results: https://t.co/D1000RUBMV
@withpersona: Trusted identity verification for any use case: https://t.co/eF6Icbeyt3

(00:00) Introduction to Viswa Colluru
(07:06) Early pull toward technology
(14:24) Studying Biotechnology
(24:23) Innovation vs. novelty
(32:05) Joining Recursion
(40:42) What launched Enveda
(49:53) Chemistry-first approach
(52:17) Raising $225K and investing $55K personally
(56:04) Initial studies and targets
(1:18:27) Enveda’s long-term vision
(1:21:31) Book recommendation

[Enveda @lifeschemistry]

Innovation doesn’t stop at the bench.

Clinical trials are the bottleneck, but they don’t have to be.

We’re scaling a multi-asset clinical pipeline across large indications. Now we scale execution.

Welcoming Chris Porter (25+ yrs scaling global clinical programs).

AI/Nature-driven discovery × world-class clinical ops
= faster path to new medicines

Welcome, Chris 🚀

Read more: https://t.co/yiqf0k73dc

[Zavain Dar @zavaindar]

the first public sneak peek of data from @lifeschemistry's first clinical trials

this is small early data, but has the potential to be:
1) clinically differentiated and meaningfully best in class
2) small molecule vs injectable
3) active in an all-patient population, including for non responders to IL-4/IL-13/STAT6 pathway

[Finn Murphy @FinnMurphy12]

We waste too much time worrying about short term hype. Hyper-fixating on the news cycle isn’t going to fix the biggest problems facing society in the coming decades.

The world needs more long term thinking.

So we are launching Forecast 2050: a series of conversations with the thinkers, founders, and investors shaping the next 25 years.

Thank you to @tylercowen, Scott Aaronson, @noor_siddiqui_, @soundboy, @matthewclifford, @devonzuegel, @CJHandmer, @MalcolmRifkind, Yanai Yedvab, @viswacolluru, @pablolubroth, and @PhilipJohnston for joining us.

First episode with Tyler drops tomorrow. Stay tuned.

[Enveda @lifeschemistry]

Thanks @WSJ for featuring us as part of the positive #biotech outlook for 2026!

We are doing our part with the first differentiated clinical signal in a competitive, blockbuster market!

Stay tuned for more
https://t.co/HRpBIIPCiO

[Viswa Colluru @viswacolluru]

On Tuesday at #JPM26, I’ll start with ENV-294.
Strong Phase 1b data in moderate-to-severe AD with clean safety and best-in-disease potential.

More than a drug, it’s proof that the system we built works.

ENV-294 is the moment where promise becomes proof!.

[Enveda @lifeschemistry]

Six years ago, this was a thesis. Today, it’s clinical data.

Next week at #JPM26, we’ll be sharing progress that reflects years of deliberate choices coming together.
Our oral therapy for atopic dermatitis, ENV-294, has generated compelling Phase 1b data showing strong clinical activity and a clean safety profile in one of the largest and most competitive categories in medicine. The signal supports best-in-disease potential and represents exciting clinical proof of the thesis Enveda was built on.

ENV-294 matters not just because it is a strong program, but because it is the output of a system we have been building since day one. A company singularly focused on discovering, developing, and delivering breakthrough medicines with the potential to not just capture, but create markets.

We now have three assets in the clinic:

ENV-294 in atopic dermatitis and asthma, now in Phase 2a with a Jak-like efficacy and a Dupi-like safety profile

ENV-308 for obesity, with the first patient dosed in Phase 1, a “statin for obesity”, engineered for a post-GLP1 world

ENV-6946 for IBD, bringing together clinically validated biology across TNFa, TL1A, IL23, and NLRP3, via a single novel-target delivered in a convenient pill

With additional INDs expected in 2026, Enveda is now a multi-asset clinical-stage company with a highly concentrated set of upcoming catalysts.

Looking ahead over the next several quarters, this foundation provides both momentum and resilience. It positions us to move quickly, take meaningful swings, and continue building a generational company that endures.

We look forward to sharing more next week in San Francisco.

#JPM26 #ENV294 #ENV308 #DrugDiscovery #ClinicalTrials #Biotech #Enveda #LearningFromLife #RevolutionizingImmunology #RevolutionizingObesity

[Viswa Colluru @viswacolluru]

@zavaindar lol

[Zavain Dar @zavaindar]

enveda speed running: platform -> pipeline -> clinical translation might have been my favorite part of all of 2025

congrats @viswacolluru and the entire enveda team!

[Viswa Colluru @viswacolluru]

Slowly, and then all at once.

ENV-6946 puts the power of multiple blockbusters into a single pill for IBD.

Let’s go! 🚀

[Enveda @lifeschemistry]

One more thing.

We have received another FDA IND clearance and have initiated Phase 1 for ENV-6946, bringing our total to three first-in-class, novel, nature-inspired molecules in the clinic.

ENV-6946 is an oral small molecule engineered for the potential to treat inflammatory bowel disease, designed as a “multi-biologic in a pill.” It simultaneously targets TNFα, IL-23, and TL1A signaling in the gut without requiring separate injectable therapies.

Millions of people live with IBD, with far too few efficacious, safe, durable, and convenient options available. ENV-6946 represents a new path forward – one designed for efficacy, safety, and simplicity.

With ENV-294, ENV-308, and now ENV-6946 in clinical development, we continue to demonstrate:

• The ingenuity of nature
• The power of our platform
• The pace and commitment of our team

Onward.

Read more: https://t.co/GH04ifkwyb

[Zavain Dar @zavaindar]

in context of the dave ricks cheeky pint podcast making the rounds

at Enveda we're now dosing patients with a new molecule: entirely distinct from the GLP-GIP axes, with the promise to be uncompromising on distinguishing unwanted fat vs lean muscle, avoidant of nausea and other adverse effects that uniformly plague existing drugs, and taken daily as a pill

the potential new statin

[Enveda @lifeschemistry]

We are proud to announce our latest milestone at Enveda:

FDA IND clearance and first patient dosed for ENV-308, our first-in-class oral therapy for obesity.

GLP-1s changed expectations for weight loss. But they also raised challenging questions:

Can patients stay on them long term?

What happens after weight loss?

Who can realistically access injectable medicines on a global scale?

ENV-308 is a once-daily oral small molecule designed with exciting potential for durability, tolerability, and real-world use. It’s built for long-term metabolic health, not just short-term weight loss. And it’s designed to fit into everyday life, earlier in care and over years, not months.

Obesity is a chronic disease. Solving it at the population scale will require new tools, new thinking, and medicines designed to last.

This milestone is a first step.

And yes, we are now a multi-asset clinical-stage company!

Read more: https://t.co/EJgeRSsX4U

[Enveda @lifeschemistry]

We are excited to welcome Nadeem Sarwar to Enveda as SVP & Global Head of Disease Prevention and Metabolic Disease Strategy.

Nadeem brings rare experience from the front lines of metabolic medicine, as the former Co-Founder and Head of the Transformational Prevention Unit (TPU) at @novonordisk , where he helped shape the industry's approach to obesity, risk, and long-term health.

At Enveda, we believe the future of medicine is not just treating disease, but ensuring long-term benefit or even preventing it before it takes hold. With our first-in-class oral metabolic program now in the clinic, Nadeem will help unlock the next chapter: medicines designed for durability, scalability, and real-world use.

This isn’t just about doing things differently. It’s about raising the bar for what patients can expect.

We are thrilled to help build a healthier future for society.

Welcome to Enveda, Nadeem.

Read more: https://t.co/EJgeRSsX4U

[Viswa Colluru @viswacolluru]

LFG 🚀

[Enveda @lifeschemistry]

Delivering on our promise…

We started with a simple thesis: nature has given us history’s best medicines, and with the right technology, we can find, understand, and develop the next generation of breakthroughs.

This week, our thesis turned into real clinical momentum.

- We obtained compelling interim Phase 1b data in atopic dermatitis, showing robust activity and a clean safety profile.

- We initiated parallel Phase 2a studies of ENV-294 for atopic dermatitis and asthma, our first-in-class oral small molecule for inflammatory disease.

Running two Phase 2a trials accelerates how quickly we can validate the breadth of ENV-294’s “pipeline-in-a-product” potential across inflammatory biology.

And we’re not slowing down: A global Phase 2b dose-ranging is targeted to begin in 2026 to accelerate the development path.

This is the kind of velocity we built Enveda to deliver. We are just getting started.

See here for more information: https://t.co/9mfR2CBAOe

[Nathan Benaich @nathanbenaich]

🪩The one and only @stateofai 2025 is live! 🪩

It’s been a monumental 12 months for AI. Our 8th annual report is the most comprehensive it's ever been, covering what you *need* to know about research, industry, politics, safety and our new usage data.

My highlight reel:

[Enveda @lifeschemistry]

Raising $150M wasn’t the only headline.

Discovery is nothing without delivery
ENV-294, our lead drug for #atopicdermatitis, has entered Phase 1b. A completely new way of tackling this disease, and potentially others across #inflammation, is playing out in patients.

Experience that shapes the industry
Mikael Dolsten joins Enveda. Former CSO of Pfizer, with 36 approvals and 150+ candidates. He knows what it takes to turn science into #medicines that matter.

This is just the beginning.

Read more in our announcement: https://t.co/1wE3tA4mRy

[Enveda @lifeschemistry]

#Nature just got its #unicorn.

Enveda raised $150M to turn the oldest source of #medicine into the newest frontier of #biotech. Thank you Brian Gormley for featuring Enveda in the @WSJ: https://t.co/bVQJ1dhmbf

If you’re not watching, you should be. Follow-us!